Pioneering first-in-class neuroplasticity modulators for unmet medical needs in CNS disorders

Barcelona, Spain
We have initiated our Phase IIa clinical trial of #CTH120 in #FragileXSyndrome (FXS)! This marks a major milestone for @ConnectaThx, bringing us one step closer to evaluating its potential as a therapy for a condition with no approved targeted treatments. #FXS #RareDisease
1
230
💜 It’s #ChildNeurologyAwarenessDay! @ConnectaThx is advancing #CTH120, a first-in-class therapy now starting the pediatric development for Fragile X Syndrome (#FXS) supported by the EU-funded #FRAXCURE project. #ChildNeurology #RareDisease
1
2
65
💜 October is #RettSyndromeAwareness Month! At @ConnectaThx, we stand with the global Rett community and are dedicated to advancing science that tackles the root causes of #RareDisease. #RettSyndromeAwareness #NeurodevelopmentalDisorders
1
1
59
🧠 October is #ADHDAwarenessMonth! At @ConnectaThx, we’re developing #neuroplasticity modulators that aim to go beyond symptoms and target underlying pathways in #ADHD and other #CNS disorders. 🙏 Thanks @ADHDMonth for shining a light on the many faces of ADHD!
1
2
40
CONNECTA Therapeutics retweeted
NEWS | @VHIR_ and Prous Institute will promote high-impact research projects in the early stages of development 👉 tuit.cat/NdUEc
2
1
257
CONNECTA Therapeutics retweeted
@ConnectaThx avanza en su programa #CTH120 a fase II en pacientes pediátricos para el síndrome del cromosoma X frágil (SXF), tras completar con éxito la fase I. #CTH120 es la primera terapia modificadora de la enfermedad para este trastorno neurológico sin tratamiento aprobado.
🚀Big step for @ConnectaThx ! Our lead candidate #CTH120 moves to Phase II pediatric trials, co-funded by the EU with a €2.5M @EUeic Accelerator grant. Read more about our aim to deliver the first disease-modifying therapy for #FragileXSyndrome👇 bit.ly/4pft6Ly #EUeic
1
1
36
CONNECTA Therapeutics retweeted
@ConnectaThx , empresa coinvertida por Innvierte, SICC del @CDTI_innovacion, avanza hacia la Fase II del programa #CTH120, desarrollo pediátrico para el tratamiento del Síndrome X Frágil (#SXF), cofinanciado por la Unión Europea en el programa @EUeic Accelerator 👇
🚀Un gran paso para @ConnectaThx! #CTH120 avanza a ensayos clínicos pediátricos de Fase II, cofinanciado por la UE con 2,5M€ bajo el programa @EUeic Accelerator. Más información sobre nuestra primera terapia modificadora para #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic
1
1
35
CONNECTA Therapeutics retweeted
@ConnectaThx, empresa coinvertida por Innvierte, SICC del @CDTI_innovacion, avanza hacia la Fase II del programa #CTH120, desarrollo pediátrico para el tratamiento del Síndrome X Frágil (#SXF), cofinanciado por la Unión Europea en el programa @EUeic Accelerator 👇
🚀Un gran paso para @ConnectaThx! #CTH120 avanza a ensayos clínicos pediátricos de Fase II, cofinanciado por la UE con 2,5M€ bajo el programa @EUeic Accelerator. Más información sobre nuestra primera terapia modificadora para #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic
1
1
29
CONNECTA Therapeutics retweeted
NEWS | @ConnectaThx to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome 👉 tuit.cat/iQcpc
1
1
82
🚀Un gran pas per @ConnectaThx! #CTH120 avança cap a assajos clínics pediàtrics de Fase II, cofinançat per la UE amb 2,5M€ sota el programa @EUeic Accelerator. Per més informació sobre la nostra primera teràpia modificadora per #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic
1
3
46
🚀Un gran paso para @ConnectaThx! #CTH120 avanza a ensayos clínicos pediátricos de Fase II, cofinanciado por la UE con 2,5M€ bajo el programa @EUeic Accelerator. Más información sobre nuestra primera terapia modificadora para #SindromeXFragil👇 bit.ly/4pft6Ly #EUeic
1
2
98
🚀Big step for @ConnectaThx ! Our lead candidate #CTH120 moves to Phase II pediatric trials, co-funded by the EU with a €2.5M @EUeic Accelerator grant. Read more about our aim to deliver the first disease-modifying therapy for #FragileXSyndrome👇 bit.ly/4pft6Ly #EUeic
1
1
5
129
CONNECTA Therapeutics retweeted
. @ConnectaThx announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120 biotech-spain.com/en/article…
1
3
58
CONNECTA Therapeutics retweeted
. @ConnectaThx completa el ensayo clínico de Fase I de su fármaco CTH120 para el tratamiento de trastornos del neurodesarrollo biotech-spain.com/es/article…
1
1
36
CONNECTA Therapeutics announces positive results from Phase I clinical trial of neurodevelopmental disorders drug candidate CTH120: bit.ly/3QN8XMM A randomised, double-blind and placebo-controlled study that recruited 76 healthy adults at @HMar_research in Barcelona👇🏼
1
3
4
169
We are currently conducting an observational study on the biomarkers that will be used in the Phase IIa clinical trial with HMRI, @I3ptT and @CRGenomica. #FragileXSyndrome #neurology #RareDiseases #OrphanDrug
1
31
Today, February 28, is World #RareDiseasesDay, a special day to raise awareness on the extraordinary strength and resilience of 300 M people worldwide living with rare diseases. Video: youtu.be/fIvqxQPjisI
1
1
28
CONNECTA Therapeutics retweeted
🔝 España ocupa el 4º lugar en el último corte 2024 del Acelerador #EIC de #HorizonteEuropa 🇪🇺👏 6⃣ empresas españolas de las 71 financiadas 🤝 79% financiación mixta; 100% de las españolas 💶 387M€ presupuesto total estimado ➡ @CDTI_innovacion apoya a los participantes a través de los #NCPs @HorizonteEuropa con simulacros de entrevistas, evaluación de las propuestas y asesoramiento Más información ➡️acortar.link/YC2wwO #UE #AyudandoCrearFuturo
1
5
9
600
We are honored to announce that @ConnectaThx has been selected for grant and equity funding under the #EICAccelerator from the @EU_EISMEA. The EIC funding will boost our neurodevelopmental clinical developments in #FragileXsyndrome.
New companies selected under EIC Accelerator! 🚀 71 companies have been chosen for funding under #EUeic Accelerator in the most competitive funding round so far since the launch of the Accelerator under Horizon Europe. Learn more 👉 europa.eu/!4vxDGm @EZaharievaEU
1
1
19